---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336864"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-08-06T12:15:17+00:00"
generated_at: "2026-08-06T12:20:09.652604+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corbus reports Q2 net loss of $35M; cash $117.9M; FDA clearance for CRB-701 registrational study

## Summary
- Net loss of $35.0M ($1.81 per share) vs $17.7M ($1.44) in Q2 2025; operating expenses rose to $36.2M including $10M milestone payment.
- Cash and investments $117.9M as of June 30, 2026, expected to fund operations into 2028.
- FDA cleared TEMPO-1 registrational study (n=250) of CRB-701 in 2L oropharyngeal cancer; enrollment to start September 2026.
- CANYON-1 Phase 1b study of CRB-913 in obesity completed last patient visit; topline data expected September 2026.
- Appointed new CMO (Dr. Leonardo Viana Nicacio), CBO (Nishant Saxena), and Board member (Brent Pfeiffenberger).

## SEC filing metadata
- accession: 0001193125-26-336864
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-08-06T12:15:17+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/0001193125-26-336864-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336864
- JSON: https://secwatch.observer/filing/0001193125-26-336864.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336864.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.